Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy
- 1 January 1996
- journal article
- research article
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 19 (3), 340-346
- https://doi.org/10.1002/(sici)1096-9101(1996)19:3<340::aid-lsm10>3.0.co;2-8
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Clinical pharmacokinetic studies of tetra(meta‐hydroxyphenyl)chlorin in squamous cell carcinoma by fluorescence spectroscopy at 2 wavelengthsInternational Journal of Cancer, 1995
- Clinical pharmacokinetic studies of photofrin by fluorescence spectroscopy in the oral cavity, the esophagus, and the bronchiCancer, 1995
- Evaluation of a new photosensitizer, meso‐tetra‐hydroxyphenyl‐chlorin, for use in photodynamic therapy: A comparison of its photobiological properties with those of two other photosensitizersInternational Journal of Cancer, 1994
- Selectivity ofmeso-tetra(hydroxyphenyl)porphyrins and chlorins and of photofrin II in causing photodamage in tumour, skin, muscle and bladder. The comcept of cost-benefit in analysing the resultsLasers in Medical Science, 1993
- Photodynamic therapy of lung cancer.Thorax, 1993
- THE UPTAKE OF PORPHYRIN AND ZINC-METALLOPORPHYRIN BY THE PRIMATE PROSTATEPhotochemistry and Photobiology, 1993
- Effect of drug-light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant mesotheliomaInternational Journal of Cancer, 1993
- HOW DOES PHOTODYNAMIC THERAPY WORK?Photochemistry and Photobiology, 1992
- Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical resultsBritish Journal of Cancer, 1991
- Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizersBiochemical Journal, 1989